FDA-cleared profile

StrokeSENS ASPECTS Software Application

Circle Cardiovascular Imaging Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: ASPECTS scoring and highlighted-region/voxel visualization to assist assessment of ischemic brain injury in known MCA/ICA occlusion within 12 hours from last known well.

Clinical role
CADx decision support in parallel with standard-of-care interpretation; automated ASPECTS results are gated by clinician confirmation and remain editable/verified before archiving or PACS transfer.
Images and patients
CT/CTA · Brain ASPECTS regions in patients with known MCA or ICA occlusion
Key limitation
Keep in mind: Not intended for primary CT interpretation. It is validated for known MCA/ICA occlusion and brain ischemia within 12 hours from last known well in patients over 21. It is contraindicated for other neurological pathologies such as tumors, abscesses, hemorrhagic transformation, or hematoma; excessive motion can make scans technically inadequate.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: ASPECTS scoring and highlighted-region/voxel visualization to assist assessment of ischemic brain injury in known MCA/ICA occlusion within 12 hours from last known well.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain ASPECTS regions in patients with known MCA or ICA occlusion Input: DICOM non-contrast head CT from patients with known MCA or ICA occlusion, acute ischemic stroke workup within 12 hours from last known well, and age over 21; users must confirm the occlusion before accessing ASPECTS results.
  • Who uses it?Intended users: Clinicians, with standard-of-care radiologist review; the physician confirms the MCA/ICA occlusion and reviews, verifies, or modifies the result.
  • What does the software produce?Output: Automated ASPECTS score; highlighted affected ASPECTS regions; affected side; voxel-wise VCTA heatmap; original and annotated images; and a user-verified or modified result summary that can be sent to PACS via DICOM.
  • What is its most important limitation?Key limitation: Not intended for primary CT interpretation. It is validated for known MCA/ICA occlusion and brain ischemia within 12 hours from last known well in patients over 21. It is contraindicated for other neurological pathologies such as tumors, abscesses, hemorrhagic transformation, or hematoma; excessive motion can make scans technically inadequate.

Clinical takeaway. Clinical role: ASPECTS scoring and highlighted-region/voxel visualization to assist assessment of ischemic brain injury in known MCA/ICA occlusion within 12 hours from last known well.

Evidence takeaway. Evidence from the reviewed source record: FDA standalone validation used 200 NCCT scans from acute ischemic stroke patients with confirmed ICA/MCA occlusion. Region-level clustered ROC analysis reported AUC-ROC 90.9% (95% CI 88.7%-93.1%), accuracy 90.6% (95% CI 89.7%-91.5%), sensitivity 70.6% (95% CI 69.2%-72.1%), and specificity 93.9% (95% CI 93.2%-94.7%). A separate 100-scan MRMC reader study with eight readers reported aided versus unaided AUC 74.3% versus 68.6%, sensitivity 51.0% versus 41.3%, specificity 97.5% versus 95.9%, accuracy 92.0% versus 89.5%, and Fleiss kappa 60.8% versus 32.3%; VCTA concordance was 97.0%.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
ASPECTS scoring and highlighted-region/voxel visualization to assist assessment of ischemic brain injury in known MCA/ICA occlusion within 12 hours from last known well.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
CADx decision support in parallel with standard-of-care interpretation; automated ASPECTS results are gated by clinician confirmation and remain editable/verified before archiving or PACS transfer.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
DICOM non-contrast head CT from patients with known MCA or ICA occlusion, acute ischemic stroke workup within 12 hours from last known well, and age over 21; users must confirm the occlusion before accessing ASPECTS results.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Automated ASPECTS score; highlighted affected ASPECTS regions; affected side; voxel-wise VCTA heatmap; original and annotated images; and a user-verified or modified result summary that can be sent to PACS via DICOM.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Diagnostic imaging workup for acute ischemic stroke with known MCA or ICA occlusion
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Clinicians, with standard-of-care radiologist review; the physician confirms the MCA/ICA occlusion and reviews, verifies, or modifies the result.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Not intended for primary CT interpretation. It is validated for known MCA/ICA occlusion and brain ischemia within 12 hours from last known well in patients over 21. It is contraindicated for other neurological pathologies such as tumors, abscesses, hemorrhagic transformation, or hematoma; excessive motion can make scans technically inadequate.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA standalone validation used 200 NCCT scans from acute ischemic stroke patients with confirmed ICA/MCA occlusion. Region-level clustered ROC analysis reported AUC-ROC 90.9% (95% CI 88.7%-93.1%), accuracy 90.6% (95% CI 89.7%-91.5%), sensitivity 70.6% (95% CI 69.2%-72.1%), and specificity 93.9% (95% CI 93.2%-94.7%). A separate 100-scan MRMC reader study with eight readers reported aided versus unaided AUC 74.3% versus 68.6%, sensitivity 51.0% versus 41.3%, specificity 97.5% versus 95.9%, accuracy 92.0% versus 89.5%, and Fleiss kappa 60.8% versus 32.3%; VCTA concordance was 97.0%.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA standalone validation used 200 NCCT scans from acute ischemic stroke patients with confirmed ICA/MCA occlusion. Region-level clustered ROC analysis reported AUC-ROC 90.9% (95% CI 88.7%-93.1%), accuracy 90.6% (95% CI 89.7%-91.5%), sensitivity 70.6% (95% CI 69.2%-72.1%), and specificity 93.9% (95% CI 93.2%-94.7%). A separate 100-scan MRMC reader study with eight readers reported aided versus unaided AUC 74.3% versus 68.6%, sensitivity 51.0% versus 41.3%, specificity 97.5% versus 95.9%, accuracy 92.0% versus 89.5%, and Fleiss kappa 60.8% versus 32.3%; VCTA concordance was 97.0%.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
70.6% (95% CI: 69.2%, 72.1%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
93.9% (95% CI: 93.2%, 94.7%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

StrokeSENS ASPECTS Software Application regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K250221
  • Samplen=200
  • IndependenceIndependence not established

K250221

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K250221. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM non-contrast head CT from patients with known MCA or ICA occlusion, acute ischemic stroke workup within 12 hours from last known well, and age over 21; users must confirm the occlusion before accessing ASPECTS results.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K250221: StrokeSENS ASPECTS Software Application

  2. Routing

    Source context, not route validation: Connects with DICOM-compliant devices, processes images using preconfigured DICOM routing, and sends results/images to PACS via DICOM for viewing on a PACS workstation, StrokeSENS UI, or another DICOM-compatible viewer. Results are clinician-verifiable and editable.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K250221: StrokeSENS ASPECTS Software Application

  3. AI processing

    Source context, not route validation: The exact FDA package describes the subject device's computer platform as a standard off-the-shelf server or virtual server. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Design: Computer Platform Standard off-the-shelf server or virtual server Standard off-the-shelf server or virtual server" … "Feature Subject Device Predicate Device StrokeSENS ASPECTS Brainomix 360 e-ASPECTS (K221564)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K250221: StrokeSENS ASPECTS Software Application

  4. Returned objects

    Source context, not route validation: Automated ASPECTS score; highlighted affected ASPECTS regions; affected side; voxel-wise VCTA heatmap; original and annotated images; and a user-verified or modified result summary that can be sent to PACS via DICOM.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K250221: StrokeSENS ASPECTS Software Application

  5. Viewer/worklist/report

    Unresolved route: Automated ASPECTS score; highlighted affected ASPECTS regions; affected side; voxel-wise VCTA heatmap; original and annotated images; and a user-verified or modified result summary that can be sent to PACS via DICOM.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K250221: StrokeSENS ASPECTS Software Application

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes the subject device's computer platform as a standard off-the-shelf server or virtual server. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Design: Computer Platform Standard off-the-shelf server or virtual server Standard off-the-shelf server or virtual server" … "Feature Subject Device Predicate Device StrokeSENS ASPECTS Brainomix 360 e-ASPECTS (K221564)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
Connects with DICOM-compliant devices, processes images using preconfigured DICOM routing, and sends results/images to PACS via DICOM for viewing on a PACS workstation, StrokeSENS UI, or another DICOM-compatible viewer. Results are clinician-verifiable and editable.
  • Exact FDA submission
  • Checked 2026-09-08

Result destination

PACS is explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for StrokeSENS ASPECTS Software Application; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K250221
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Brain ASPECTS regions in patients with known MCA or ICA occlusion
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-07-01
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K250221 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K250221: StrokeSENS ASPECTS Software Application

    U.S. Food and Drug Administration - Published 2025-07-01 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. StrokeSENS ASPECTS Software Application model card (K250221)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K250221

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K250221 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253560

Enhanced Boundary for PCCT

Ge Medical Systems, LLC

Authorized purpose: Enhanced Boundary for PCCT is a deep-learning CT processing function for improved soft-tissue delineation in routine head examinations with or without contrast.

Modality
CT/CTA
Anatomy
Head
Decision
2026-06-24
FDA-cleared K253649

Spectral CT Verida Family

Philips Medical Systems Technologies, Ltd.

Authorized purpose: Spectral CT Verida Family supports the labeled spectral CT acquisition, reconstruction, material-map, and professional-interpretation workflow; exact models, protocols, and derived outputs remain submission-specific.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K253574

SOMATOM X.cite; SOMATOM X.ceed

Siemens Medical Solutions USA, Inc.

Authorized purpose: SOMATOM X.cite and X.ceed with syngo CT VB20 support diagnostic CT, interventions, treatment preparation, radiation-therapy planning, and qualified low-dose lung screening.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-20
FDA-cleared K252041

Fibresolve (with PCCP)

Imvaria, Inc.

Authorized purpose: Fibresolve analyzes lung CT in patients with pulmonary symptoms to provide an adjunct diagnostic-subtype classification for suspected interstitial lung disease and support referral to a multidisciplinary discussion.

Modality
CT/CTA
Anatomy
Lungs and interstitial lung disease patterns
Decision
2025-11-07

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history